🇺🇸 FDA
Pipeline program

Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses

OBU-BC-II-206

Approved small_molecule active

Quick answer

Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses for HER2 Positive Breast Cancer is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
HER2 Positive Breast Cancer
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials